| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 59.79% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 07/21/2023 | 59.79% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 06/21/2023 | 59.79% | Truist Securities | $22 → $24 | Maintains | Buy |
| 06/21/2023 | 66.44% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 06/20/2023 | 59.79% | Truist Securities | $22 → $24 | Maintains | Buy |
| 05/12/2023 | 59.79% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 03/20/2023 | 59.79% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 01/19/2023 | 46.47% | Truist Securities | $18 → $22 | Maintains | Buy |
| 12/21/2022 | 19.84% | Truist Securities | $17 → $18 | Maintains | Buy |
| 12/21/2022 | 59.79% | HC Wainwright & Co. | $18 → $24 | Maintains | Buy |
| 12/20/2022 | 33.16% | Piper Sandler | $18 → $20 | Maintains | Overweight |
| 08/24/2022 | 3.2% | Roth Capital | $10 → $15.5 | Downgrades | Buy → Neutral |
| 08/11/2022 | 13.18% | Truist Securities | $12 → $17 | Maintains | Buy |
| 08/11/2022 | 19.84% | HC Wainwright & Co. | $12 → $18 | Maintains | Buy |
| 02/08/2022 | -20.11% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 03/18/2021 | -53.4% | Roth Capital | $6.5 → $7 | Maintains | Buy |
| 08/12/2020 | -46.74% | Truist Securities | $10 → $8 | Maintains | Buy |
| 05/13/2020 | -33.42% | SunTrust Robinson Humphrey | $11 → $10 | Maintains | Buy |
| 02/14/2020 | -20.11% | Cantor Fitzgerald | $11 → $12 | Reiterates | → Overweight |
| 12/13/2018 | -50.07% | Piper Sandler | $5 → $7.5 | Maintains | Overweight |
| 11/29/2018 | -46.74% | Cantor Fitzgerald | → $8 | Reiterates | → Overweight |
| 09/21/2018 | -46.74% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
What is the target price for Catalyst Pharmaceuticals (CPRX)?
The latest price target for Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $24.00 expecting CPRX to rise to within 12 months (a possible 59.79% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Catalyst Pharmaceuticals (CPRX)?
The latest analyst rating for Catalyst Pharmaceuticals (NASDAQ: CPRX) was provided by HC Wainwright & Co., and Catalyst Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Catalyst Pharmaceuticals (CPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Catalyst Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Catalyst Pharmaceuticals was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating Catalyst Pharmaceuticals (CPRX) correct?
While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a reiterated with a price target of $0.00 to $24.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $15.02, which is within the analyst's predicted range.